

SYNTHESIS OF A NOVEL ARTEMISININ ANALOGUE HAVING POTENT ANTIMALARIAL ACTIVITY[†]

Kiyosei Takasu,^{*} Ruriko Katagiri, Yuko Tanaka, Masahiro Toyota, Hye-Sook Kim,[#] Yusuke Wataya,[#] and Masataka Ihara^{*}


Department of Organic Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Aobayama, Sendai 980-8578, Japan

[#]Faculty of Pharmaceutical Sciences, Okayama University, Tsushimanaka 1-1-1, Okayama, Japan

E-mail: mihara@mail.pharm.tohoku.ac.jp

Abstract—An artemisinin analogue containing 1,2,4-trioxane structure was designed and synthesized. The compound exhibited significant and selective *in vitro* antimalarial activity.

Malaria is one of the most serious infectious diseases in tropical and subtropical area. Recently, development of a new class of antimalarial drugs is strongly required due to the problem of chloroquine-resistant *Plasmodium falciparum*, malaria parasite. Artemisinin (**1**, qinghaosu),¹ which contains an unusual cyclic peroxy structure, has become an important clinical drug for the treatment of the drug-resistant strains. Many of cyclic peroxy compounds as an artemisinin derivative have been synthesized or semi-synthesized, and some of them actually demonstrated effective antimalarial activities.^{2,3} 1,2,4-Trioxane unit was recognized as the essential structure for high efficacy during the investigation of structure-activity relationships about the parent drug. We have designed a modified artemisinin derivative by the introduction of ketocarbonyl oxygen to the C(6) position shown in the partial structure (**2**) as a divergent scaffold for further structural derivation. Several methods for 1,2,4-trioxane framework construction have been reported,⁴ for example, Roth reported the construction of 1,2,4-trioxane structure (**3**) from dehydrodecaline (**4**, artemisinic acid) by double oxidation using molecular oxygen.^{4a} Hence, we




[†] Dedicated to Professor Sho Ito on the occasion of his 77th Birthday.

planned that the analogue (**2**) might be synthesized from the corresponding octalone by utilizing Roth's method. In this communication, we report the synthesis and antimalarial evaluation of a new class of artemisinin analogue.⁵

Octalone (**5**) was synthesized as shown in Scheme 1, by an alternative method to that reported by Parker.⁶ Thus, the known bis-allylic alcohol (**6**)⁶ was acylated with propionyl chloride to give ester (**7**) in 86% yield. Treatment of **7** with LDA in the presence of TMSCl at low temperature promoted regio- and stereoselective Ireland-Claisen rearrangement.⁷ After its esterification with CH₂N₂, diene (**8**) having (*l, E*) configuration was preferentially obtained in 72% yield (2 steps). The excellent regio- and stereoselectivity could be explained by the formation of *Z*-enolate from **7** which is in agreement with Parker's previous results. THP group of **8** was deprotected in MeOH containing a catalytic amount of *p*-toluenesulfonic acid to provide alcohol (**9**) in 94% yield. Oxidation of **9** with PDC, followed by the addition of vinylmagnesium bromide, afforded triene (**10**) in 65% yield for 2 steps. The construction of *cis*-octalone (**5**) was accomplished by Dess–Martin oxidation of **10**, followed by the subsequent spontaneous Diels–Alder reaction of the corresponding intermediate (**11**). Compound (**5**) was obtained in 78% yield as a sole diastereomer, whose configuration was confirmed by the NOESY spectrum. The diastereoselectivity was very high as expected from the previous results.^{7,8}

Scheme 1




(a) C₂H₅COCl, pyridine, rt; (b) LDA, -78 °C; TMSCl, to rt; (c) CH₂N₂, rt; (d) TsOH, H₂O, rt; (e) PDC, molecular sieves 4Å, rt; (f) CH₂=CHMgBr, -78 °C; (g) Dess–Martin reagent, rt

Although the oxidation of **5** was investigated under several conditions analogous to Roth's method,^{4a} no 1,2,4-trioxane was obtained. We suspected that the lack of reactivity was due to the relative *trans*-configuration between C(6) and C(10) of **5**, whereas Roth's **4** has *cis* stereochemistry. That is, 1,2,4-trioxane would be obtained from *trans*-octalone (**12**).

Treatment of **5** with sodium hydride in THF led to a mixture of ketones (**5**) and (**12**) in a ratio of approximately 55 : 45. Exposure of the epimerized ketone mixture under Roth's conditions gave *endo*-

peroxy compound (**14**) in 5% yield based on **5**. Namely, **12** was irradiated with 100W tungsten lamp in acetone containing catalytic amount of methylene blue under O₂ current to produce tertiary hydroperoxide (**13**) *in situ*. Treatment of crude **13** with a catalytic amount of trifluoroacetic acid and atmospheric oxygen afforded **14**.⁹ The ¹H NMR spectrum exhibited characteristic singlet (5.80 ppm), which corresponds to acetal hydrogen attached to C(1). The IR spectrum indicated the existence of hydroxyl function (3500–3200 cm⁻¹) and peroxy ether (1160 cm⁻¹). The structure of **14** was firmly determined by the 2D NMR technique. Due to the intramolecular hydrogen bonding, β-hydroxyl group would be thermodynamically favorable. Consequently, the lactonization could not occur although artemisinin analogues generally undergo lactonization.



Antimalarial effectiveness of 1,2,4-trioxane (**14**) and synthetic intermediate (**12**) against *P. falciparum* was investigated *in vitro* (Table 1).¹⁰ Compound (**14**) possesses a remarkable antimalarial activity, IC₅₀ = 3.9 × 10⁻⁸ (M), comparable to natural artemisinin (**1**). Notably, the selective toxicity is quite high (>1,000). On the contrary, **12** having no trioxane structure showed much weaker activity than **14**.

In summary, a new class of artemisinin analogue having a keto carbonyl group at the C(6) position was synthesized and evaluated for the antimalarial activity. Its promising activity suggests a possibility of a lead compound for antimalarial agent. Further modification of analogue and the optimization of its synthetic strategy are now in progress.

ACKNOWLEDGEMENT

This work was partially supported by a Grant-in-Aid for Scientific Research on Priority Areas (No. 1147202) from the Ministry of Education, Science, Sports, and Culture, Japan.

REFERENCES AND NOTES

- (a) D. L. Klayman, *Science*, 1985, **228**, 1049. (b) W.-S. Zhou and X.-X. Xu, *Acc. Chem. Res.*, 1994,

Table 1 *In Vitro* Antimalarial Activities and Cytotoxicities

compound	IC ₅₀ (M)		selective toxicity ^c
	<i>P. falciparum</i> ^a	FM3A cell ^b	
(±)- 14	3.9 × 10 ⁻⁸	2.4 × 10 ^{-5 d}	>1,000
(±)- 12	5.8 × 10 ^{-5 e}	—	—
(+)-artemisinin (1)	7.9 × 10 ⁻⁹	1.0 × 10 ⁻⁵	1,300

^a Chloroquine sensitive strain (FCR-3). ^b Mouse mammary tumor FM3A cells representing a model of host. ^c Selective toxicity = IC₅₀ value for FM3A / IC₅₀ for *P. falciparum*. ^d IC₂₂ value (78% Growth of FM3A cells was observed.) ^e IC₂₂ value (78% Growth of *P. falciparum* was observed.)

27, 211.

2. For reviews. See, (a) S. R. Meshnick, T. E. Taylor, and S. Kamchonwongpaisan, *Microbiol. Rev.*, 1996, **60**, 301. (b) A. K. Bhattacharya and R. P. Sharma, *Heterocycles*, 1999, **51**, 1681.
3. H.-S. Kim, Y. Shibata, Y. Wataya, K. Tsuchiya, A. Masuyama, and M. Nojima, *J. Med. Chem.*, 1999, **42**, 2604.
4. (a) R. J. Roth and N. Acton, *J. Chem. Ed.*, 1991, **68**, 612. (b) C. H. Oh, H. J. Kim, S. H. Wu, and H. S. Won, *Tetrahedron Lett.*, 1999, **40**, 8391 and references cited therein.
5. This work is under patent pending. M. Ihara, K. Takasu, H.-S. Kim, and Y. Wataya, C07D496/12.
6. K. A. Parker and J. G. Farmar, *J. Org. Chem.*, 1986, **51**, 4023.
7. R. E. Ireland, R. H. Mueller, and A. K. Willard, *J. Am. Chem. Soc.*, 1976, **98**, 2868.
8. (a) K. Mori and M. Waku, *Tetrahedron*, 1984, **40**, 305. (b) D. F. Taber and B. P. Gunn, *J. Am. Chem. Soc.*, 1979, **101**, 3992.
9. Spectral data for **14**: ^1H NMR (500 MHz, CDCl_3) δ 1.20 (3H, d, $J = 7.0$ Hz), 1.22–1.84 (4H, m), 1.86–1.89 (1H, m), 1.91 (3H, s), 2.05–2.20 (2H, m), 2.27–2.38 (2H, m), 2.54–2.61 (2H, m), 2.78 (1H, m), 3.68–3.71 (1H, m), 3.69 (3H, s), 5.80 (1H, s); IR (neat) ν 3500–3200, 1730, 1710, 1160 cm^{-1} .
10. H.-S. Kim, H. Miyake, M. Arai, and Y. Wataya, *Parasitol. Int.*, 1998, **47**, 59.